Latest PODD news

Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum

Business Wire · Fri, 18 Sep 2026 07:00:00 -0400

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About.

Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · Wed, 09 Sep 2026 17:27:09 -0400

Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Here's Why Insulet (PODD) is a Strong Growth Stock

Zacks Investment Research · Wed, 09 Sep 2026 10:45:54 -0400

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

Zacks Investment Research · Tue, 08 Sep 2026 10:26:05 -0400

PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.

Insulet (PODD) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research · Mon, 07 Sep 2026 10:40:49 -0400

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?

Zacks Investment Research · Fri, 04 Sep 2026 12:37:19 -0400

Insulet (PODD) reported earnings 30 days ago. What's next for the stock?

Baron SMID Cap ETF Q2 2026 Portfolio Activity

Seeking Alpha · Fri, 04 Sep 2026 11:10:00 -0400

During the quarter, we initiated a position in Advanced Drainage Systems, the leading U.S. manufacturer of stormwater and onsite wastewater management products. We view Axon Enterprise as a market leading "atoms plus electrons" software provider with huge competitive moats. We sold the HeartFlow position in the quarter as we grew incrementally more concerned with the presence of competitors on the market.

Market information is provided for research and visualization and is not investment advice.